Rna-based cholesterol drug shows early promise

Trial provides proof of concept for statin alternative. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS

Access through your institution Subscribe to this journal Receive 51 print issues and online access $199.00 per year only $3.90 per issue Learn more Buy this article * Purchase on

SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about

institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Fitzgerald, K. et al. _The Lancet_ http://dx.doi.org/10.1016/S0140-6736(13)61914-5 (2013). * Tabernero, J.

et al. _Cancer Discov._ 3, 406-417 (2013). Article  CAS  Google Scholar  * Coelho, T. et al. _New Eng. J. Med._ 369, 819-829 (2013). Article  CAS  Google Scholar  Download references

Authors * Heidi Ledford View author publications You can also search for this author inPubMed Google Scholar RELATED LINKS RELATED LINKS RELATED LINKS IN NATURE RESEARCH Genetics: A gene of

rare effect 2013-Apr-09 Cholesterol limits lose their lustre 2013-Feb-26 Drug giants turn their backs on RNA interference 2010-Nov-23 RELATED EXTERNAL LINKS Alnylam Pharmaceuticals RIGHTS

AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Ledford, H. RNA-based cholesterol drug shows early promise. _Nature_ (2013).

https://doi.org/10.1038/nature.2013.13873 Download citation * Published: 03 October 2013 * DOI: https://doi.org/10.1038/nature.2013.13873 SHARE THIS ARTICLE Anyone you share the following

link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature

SharedIt content-sharing initiative